Avance Biosciences showcases its new Next-Generation Sequencing Center, equipped with advanced technologies.
Avance Biosciences has officially launched its Next-Generation Sequencing (NGS) Center of Excellence in Houston, Texas. This state-of-the-art facility aims to enhance and unify sequencing capabilities throughout all phases of drug development. The NGS Center offers comprehensive sequencing services for various applications, including preclinical and clinical studies, and is equipped with advanced technologies to deliver precise genetic analysis. With a commitment to regulatory-compliant testing, Avance seeks to support the evolving needs of the biotechnology sector and drug developers.
The NGS Center offers comprehensive sequencing services for research purposes, preclinical and clinical studies, diagnostic support, and Good Manufacturing Practice (GMP)-compliant testing for biologics, cell and gene therapies. The establishment of this center highlights Avance Biosciences’ commitment to providing innovative solutions within the biotechnology sector.
At the heart of the NGS Center is the integration of various leading sequencing platforms, including Illumina, Element Biosciences, Oxford Nanopore, and PacBio, enabling both short- and long-read sequencing. Additionally, the facility employs advanced single-cell technologies such as 10x Genomics Chromium and Mission Bio’s Tapestri to deliver precise genetic analysis critical for modern drug development.
The NGS Center supports a wide range of drug modalities including biologics, RNA therapeutics, and cell and gene therapies. This makes it a vital resource for pharmaceutical and biotechnology developers seeking accurate sequencing data that meets stringent regulatory standards.
The facility is backed by in-house bioinformatics and cross-functional scientific teams, allowing for an enriched collaboration that bolsters the delivery of advanced sequencing solutions. Services provided at the center include GMP drug substance characterization, product lot release, as well as CLIA-compliant assays and diagnostics validation.
Avance Biosciences has been at the forefront of GMP-compliant NGS testing since 2013, positioning itself as a leader in the field of regulated sequencing services. This experience solidifies clients’ trust in the organization not only for technical capabilities but also for regulatory insights crucial to advancing drug development programs.
The NGS Center aims to ensure that advanced and cost-effective NGS testing can be conducted domestically within the United States. This strategy allows clients to maintain control over their samples while benefiting from high-quality sequencing services, reinforcing the commitment to advancing drug development with integrity.
A multidisciplinary team of experts specializing in molecular biology, genomics, assay development, and bioinformatics leads the operations of the NGS Center. These professionals are dedicated to providing complete solutions which include early-phase development, method validation, and sample testing under GMP conditions.
To introduce its capabilities to clients and industry stakeholders, Avance Biosciences will host an Open House in September 2025. This event will showcase the center’s technologies, team, and services, emphasizing the organization’s ongoing mission to support drug developers through innovative and compliant testing solutions.
Avance Biosciences is a leading contract research organization based in Houston, Texas, providing Good Laboratory Practice (GLP), GMP, and CLIA-compliant testing services tailored for drug development. The company serves a global clientele in the pharmaceutical and biotechnology sectors, reinforcing its status as a vital partner in the advancement of modern medicine.
The launch of the NGS Center of Excellence marks a significant milestone for Avance Biosciences as it continues to expand its analytical and bioanalytical services in response to the evolving needs of drug developers and the broader biotech community.
News Summary Texas has passed Senate Bill 22, providing $300 million biennially for film incentives…
News Summary In response to Hurricane Beryl's impact, Houston is upgrading its infrastructure resilience by…
News Summary In May, Houston's job market saw a modest increase of 3,600 jobs, marking…
News Summary Global superstar Beyoncé is scheduled to perform at NRG Stadium in Houston as…
News Summary Houston will host a range of family-friendly activities from June 27-29, featuring concerts,…
News Summary Three women from Houston face serious charges for allegedly defrauding the government of…